Skip to main content

Our Mission

At Alexion, our mission is to transform the lives of people with rare diseases through the development and delivery of innovative medicines, as well as support technologies and healthcare services.

For over three decades, patients and their caregivers have been at the centre of everything we do. Every day, we are inspired to think differently and follow the science in order to achieve better outcomes for them and their relatives. Our mission is based on knowing who they are as individuals, beyond their disease.

Alexion In Spain

In Spain, it is estimated that nearly 3 million people suffer from rare diseases1. In 2007, Alexion opened its office in our country with the aim of offering different innovative solutions that transform the lives of people living with these types of conditions.

In 2021, a new group called Alexion, AstraZeneca Rare Disease, was created. Now, together with AstraZeneca, we have the potential to change the lives of more people worldwide.

Alexion Pharma Spain is part of the AstraZeneca Global Hub in Barcelona, the international center for scientific innovation aimed at accelerating the arrival of the next generation of treatments in the company's five key therapeutic areas: Oncology, Rare Diseases, Cardiovascular, Renal and Metabolism, Respiratory and Immunology, and Vaccines and Immunotherapies.

Rare Diseases Supported in Spain

In Spain, we work in different therapeutic areas, such as hematology, nephrology, neurology, metabolism and bone metabolism, with a special focus on the following rare diseases:

Paroxysmal Nocturnal Haemoglobinuria (PNH)

A rare, chronic, progressive, debilitating, and potentially life-threatening haematological disease. It is characterised by the destruction of red blood cell within the blood vessels (also known as intravascular hemolysis), and the activation of leukocytes and platelets, which can cause thrombosis (due to clots).

Atypical Haemolytic Uraemic Syndrome (aHUS)

A rare disease that can progressively injure vital organs, primarily the kidneys, due to the damage in blood vessels walls and the formation of clots.

Neurofibromatosis Type 1 (NF1) Plexiform Neurofibromas (PN)

A rare and progressive genetic disease characterised by benign (non-cancerous) tumors called plexiform neurofibromas (PN), which can be developed in the brain, along the spinal cord, and nerve.

Generalized Myasthenia Gravis (gMG)

A rare autoimmune disorders characterised by skeletal muscle weakness, caused by disrupted neurotransmission at the neuromuscular junction (NMJ).

Neuromyelitis Optica Spectrum Disorder (NMOSD)

A rare and autoimmune disease of the central nervous system, characterised by unpredictable relapses that can result in progressive disability.

Hypophosphatasia (HPP)

A rare, genetic and metabolic disease, characterised by the loss of bone mineralisation (hypomineralization), the process of hardening bones and teeth. This can result in poor bone growth and development, bone weakness and deformity, and other skeletal abnormalities, as well as premature loss of teeth with the root intact.

Lysosomal Acid Lipase Deficiency (LAL-D)

An ultra-rare, genetic, and progressive metabolic disease associated with multi-organ damage in infant, pediatric and adult patients. In Infants, it can cause a premature death.

Patient Support Services

Our mission to transform the lives of people with rare disease means that we innovate beyond medicine to create value-added solutions which improve the overall patient experience.

  • 3 Millones Ya No Es Raro (3 million is no longer rare) - A website where the public can find general information about rare diseases, awareness campaigns, and patients’ stories.
  • Nixi for Children - At Alexion, AstraZeneca Rare Disease, together with the Sant Joan de Déu Hospital (Barcelona), we have joined Nixi for Children to promote InfuKids, an initiative that reduce children's anxiety before and during their treatment infusion at the Day Hospital. An innovative project that aims to alleviate anxiety and make hospitalization hours more bearable.

Clinical Trials

Clinical Trials

At Alexion, we are committed to people with rare diseases. Therefore, we work to discover and develop life-changing treatments for patients with rare diseases and their relatives.

Our goal is to bring safe and effective medicines to as many patients as possible by conducting rigorous clinical trials and obtaining marketing approval in the Spanish National Health System.

As pioneers in research and development in rare diseases, we understand the urgency of developing and providing life-changing treatments, fostering a unique culture in our research laboratories that drives high-level research.

We look for ways to help patients through a rigorous scientific process. Direct participation of patients is essential in helping us design, adapt, and conduct clinical trials tailored to their unique needs.

Contact us
Careers

Career Opportunities

At Alexion, we offer a unique opportunity to launch, expand, and develop your career in an entrepreneurial, dynamic, and highly innovative environment, supported by a global organization.

Our greatest satisfaction comes from knowing that, through our work, we contribute to the society’s well-being, improving the quality of life for our patients.

Explore Careers

Transparency and Disclosure

Alexion is committed to operating with integrity, accountability and transparency, and to complying with all applicable laws and regulations in Spain.

View our disclosures of financial support to healthcare professionals and patient organizations.

2023 Disclosures 2023 Disclosures Report

Contact Information

Communication Contact Information

Ana Crespo - Communications Director Spain/Portugal

Medical Information

Product Issues Information

 

Notification of Adverse Events

 

Notification of Quality Product Issues

 

Spain Office

References

  1. Ministerio de Sanidad. Estrategia en Enfermedades Raras del Sistema Nacional de Salud. Consultado en: https://www.sanidad.gob.es/areas/calidadAsistencial/estrategias/enfermedadesRaras/docs/enfermedadesRaras.pdf Último acceso: junio 2024.

Leaving Our Site

You are now going to another site.